Financhill
Buy
80

OCGN Quote, Financials, Valuation and Earnings

Last price:
$1.13
Seasonality move :
-16.01%
Day range:
$1.11 - $1.19
52-week range:
$0.52 - $1.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
70.50x
P/B ratio:
20.92x
Volume:
4.2M
Avg. volume:
7.3M
1-year change:
-38.04%
Market cap:
$332.9M
Revenue:
$4.1M
EPS (TTM):
-$0.19

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
OCGN
Ocugen
$350K -$0.06 -69.33% -41.68% $6.50
CARM
CARISMA Therapeutics
$3.8M -$0.09 -59.23% -66.67% $1.00
HUMA
Humacyte
$1M -$0.18 81.02% -63.19% $9.83
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
XOMA
XOMA Royalty
$9.4M -- 66.03% -- $64.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
OCGN
Ocugen
$1.14 $6.50 $332.9M -- $0.00 0% 70.50x
CARM
CARISMA Therapeutics
$0.40 $1.00 $16.7M -- $0.00 0% 0.83x
HUMA
Humacyte
$2.31 $9.83 $358.3M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.69 $0.85 $4M -- $0.00 0% 0.16x
TOVX
Theriva Biologics
$0.50 $7.00 $4.1M -- $0.00 0% 0.33x
XOMA
XOMA Royalty
$27.14 $64.67 $324.8M -- $0.54 0% 30.52x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
OCGN
Ocugen
63.49% 1.089 13.41% 2.24x
CARM
CARISMA Therapeutics
-- 5.518 -- 0.86x
HUMA
Humacyte
-- 4.484 -- 3.16x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
TOVX
Theriva Biologics
-- -3.388 -- --
XOMA
XOMA Royalty
57.31% 1.450 48.26% 5.42x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
OCGN
Ocugen
-- -$14.5M -144.95% -215.5% -979.14% -$19.4M
CARM
CARISMA Therapeutics
-- -$9.3M -437.23% -437.23% -250.31% -$10.1M
HUMA
Humacyte
$370K -$23.2M -- -- 8150.68% -$28.8M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M
XOMA
XOMA Royalty
-- $5.9M -1.4% -3.3% 135.14% $2.2M

Ocugen vs. Competitors

  • Which has Higher Returns OCGN or CARM?

    CARISMA Therapeutics has a net margin of -1036.46% compared to Ocugen's net margin of -248.49%. Ocugen's return on equity of -215.5% beat CARISMA Therapeutics's return on equity of -437.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $43.6M
    CARM
    CARISMA Therapeutics
    -- -$0.22 -$36.7M
  • What do Analysts Say About OCGN or CARM?

    Ocugen has a consensus price target of $6.50, signalling upside risk potential of 470.18%. On the other hand CARISMA Therapeutics has an analysts' consensus of $1.00 which suggests that it could grow by 150%. Given that Ocugen has higher upside potential than CARISMA Therapeutics, analysts believe Ocugen is more attractive than CARISMA Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    CARM
    CARISMA Therapeutics
    1 1 0
  • Is OCGN or CARM More Risky?

    Ocugen has a beta of 4.178, which suggesting that the stock is 317.784% more volatile than S&P 500. In comparison CARISMA Therapeutics has a beta of 1.973, suggesting its more volatile than the S&P 500 by 97.32%.

  • Which is a Better Dividend Stock OCGN or CARM?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CARISMA Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. CARISMA Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or CARM?

    Ocugen quarterly revenues are $1.5M, which are smaller than CARISMA Therapeutics quarterly revenues of $3.7M. Ocugen's net income of -$15.4M is lower than CARISMA Therapeutics's net income of -$9.3M. Notably, Ocugen's price-to-earnings ratio is -- while CARISMA Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 70.50x versus 0.83x for CARISMA Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    70.50x -- $1.5M -$15.4M
    CARM
    CARISMA Therapeutics
    0.83x -- $3.7M -$9.3M
  • Which has Higher Returns OCGN or HUMA?

    Humacyte has a net margin of -1036.46% compared to Ocugen's net margin of --. Ocugen's return on equity of -215.5% beat Humacyte's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $43.6M
    HUMA
    Humacyte
    71.57% $0.28 $36M
  • What do Analysts Say About OCGN or HUMA?

    Ocugen has a consensus price target of $6.50, signalling upside risk potential of 470.18%. On the other hand Humacyte has an analysts' consensus of $9.83 which suggests that it could grow by 325.69%. Given that Ocugen has higher upside potential than Humacyte, analysts believe Ocugen is more attractive than Humacyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    HUMA
    Humacyte
    4 1 0
  • Is OCGN or HUMA More Risky?

    Ocugen has a beta of 4.178, which suggesting that the stock is 317.784% more volatile than S&P 500. In comparison Humacyte has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock OCGN or HUMA?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humacyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Humacyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or HUMA?

    Ocugen quarterly revenues are $1.5M, which are larger than Humacyte quarterly revenues of $517K. Ocugen's net income of -$15.4M is lower than Humacyte's net income of $39.1M. Notably, Ocugen's price-to-earnings ratio is -- while Humacyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 70.50x versus -- for Humacyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    70.50x -- $1.5M -$15.4M
    HUMA
    Humacyte
    -- -- $517K $39.1M
  • Which has Higher Returns OCGN or NBY?

    NovaBay Pharmaceuticals has a net margin of -1036.46% compared to Ocugen's net margin of -49.65%. Ocugen's return on equity of -215.5% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $43.6M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About OCGN or NBY?

    Ocugen has a consensus price target of $6.50, signalling upside risk potential of 470.18%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 22.83%. Given that Ocugen has higher upside potential than NovaBay Pharmaceuticals, analysts believe Ocugen is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is OCGN or NBY More Risky?

    Ocugen has a beta of 4.178, which suggesting that the stock is 317.784% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock OCGN or NBY?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or NBY?

    Ocugen quarterly revenues are $1.5M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Ocugen's net income of -$15.4M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Ocugen's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 70.50x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    70.50x -- $1.5M -$15.4M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns OCGN or TOVX?

    Theriva Biologics has a net margin of -1036.46% compared to Ocugen's net margin of --. Ocugen's return on equity of -215.5% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $43.6M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About OCGN or TOVX?

    Ocugen has a consensus price target of $6.50, signalling upside risk potential of 470.18%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1294.42%. Given that Theriva Biologics has higher upside potential than Ocugen, analysts believe Theriva Biologics is more attractive than Ocugen.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is OCGN or TOVX More Risky?

    Ocugen has a beta of 4.178, which suggesting that the stock is 317.784% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock OCGN or TOVX?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or TOVX?

    Ocugen quarterly revenues are $1.5M, which are larger than Theriva Biologics quarterly revenues of --. Ocugen's net income of -$15.4M is lower than Theriva Biologics's net income of -$4.3M. Notably, Ocugen's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 70.50x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    70.50x -- $1.5M -$15.4M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M
  • Which has Higher Returns OCGN or XOMA?

    XOMA Royalty has a net margin of -1036.46% compared to Ocugen's net margin of 54.83%. Ocugen's return on equity of -215.5% beat XOMA Royalty's return on equity of -3.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $43.6M
    XOMA
    XOMA Royalty
    -- $0.06 $198.3M
  • What do Analysts Say About OCGN or XOMA?

    Ocugen has a consensus price target of $6.50, signalling upside risk potential of 470.18%. On the other hand XOMA Royalty has an analysts' consensus of $64.67 which suggests that it could grow by 138.27%. Given that Ocugen has higher upside potential than XOMA Royalty, analysts believe Ocugen is more attractive than XOMA Royalty.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    XOMA
    XOMA Royalty
    2 1 0
  • Is OCGN or XOMA More Risky?

    Ocugen has a beta of 4.178, which suggesting that the stock is 317.784% more volatile than S&P 500. In comparison XOMA Royalty has a beta of 0.930, suggesting its less volatile than the S&P 500 by 7.022%.

  • Which is a Better Dividend Stock OCGN or XOMA?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Ocugen pays -- of its earnings as a dividend. XOMA Royalty pays out -39.59% of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or XOMA?

    Ocugen quarterly revenues are $1.5M, which are smaller than XOMA Royalty quarterly revenues of $4.3M. Ocugen's net income of -$15.4M is lower than XOMA Royalty's net income of $2.4M. Notably, Ocugen's price-to-earnings ratio is -- while XOMA Royalty's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 70.50x versus 30.52x for XOMA Royalty. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    70.50x -- $1.5M -$15.4M
    XOMA
    XOMA Royalty
    30.52x -- $4.3M $2.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 14

MiNK Therapeutics [INKT] is down 33.72% over the past day.

Buy
51
NEGG alert for Jul 14

Newegg Commerce [NEGG] is down 21.2% over the past day.

Buy
68
ATRO alert for Jul 14

Astronics [ATRO] is down 2.08% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock